Quest Diagnostics (DGX) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
February 1, 2024 6:45 AM ESTFourth quarter revenues of $2.29 billion, down 1.9% from 2022Fourth quarter reported diluted earnings per share ("EPS") of $1.70, up 95.4% from 2022; and adjusted diluted EPS of $2.15, up 8.6% from 2022Fourth quarter base business revenues of $2.25 billion, up 4.7% from 2022Fourth quarter COVID-19 testing revenues of $37 million, down 79.8% from 2022Full year revenues of $9.25 billion, down 6.4% from 2022Full year reported diluted EPS of $7.49, down 6.0% from 2022; and adjusted diluted EPS of $8.71, down 12.5% from 2022Full year base business revenues of... More
